DE102004016179A1 - Verbindungen zur Behandlung von proliferativen Prozessen - Google Patents

Verbindungen zur Behandlung von proliferativen Prozessen Download PDF

Info

Publication number
DE102004016179A1
DE102004016179A1 DE102004016179A DE102004016179A DE102004016179A1 DE 102004016179 A1 DE102004016179 A1 DE 102004016179A1 DE 102004016179 A DE102004016179 A DE 102004016179A DE 102004016179 A DE102004016179 A DE 102004016179A DE 102004016179 A1 DE102004016179 A1 DE 102004016179A1
Authority
DE
Germany
Prior art keywords
treatment
compounds
proliferative processes
proliferative
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004016179A
Other languages
English (en)
Inventor
Nveed Chaudhary
John Edward Park
Michael P Pieper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE102004016179A priority Critical patent/DE102004016179A1/de
Priority to US11/074,179 priority patent/US20060030579A1/en
Priority to PCT/EP2005/002946 priority patent/WO2005097126A1/de
Priority to JP2007505432A priority patent/JP2007530611A/ja
Priority to EP05716229A priority patent/EP1732553A1/de
Priority to CA002560131A priority patent/CA2560131A1/en
Publication of DE102004016179A1 publication Critical patent/DE102004016179A1/de
Priority to US12/963,250 priority patent/US20110076238A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Anticholinergika zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung proliferativer Prozesse.
DE102004016179A 2004-03-30 2004-03-30 Verbindungen zur Behandlung von proliferativen Prozessen Withdrawn DE102004016179A1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE102004016179A DE102004016179A1 (de) 2004-03-30 2004-03-30 Verbindungen zur Behandlung von proliferativen Prozessen
US11/074,179 US20060030579A1 (en) 2004-03-30 2005-03-07 Compounds for the treatment of proliverative processes
PCT/EP2005/002946 WO2005097126A1 (de) 2004-03-30 2005-03-19 Verbindungen zur behandlung von proliferativen prozessen
JP2007505432A JP2007530611A (ja) 2004-03-30 2005-03-19 増殖性過程の治療用化合物
EP05716229A EP1732553A1 (de) 2004-03-30 2005-03-19 Verbindungen zur behandlung von proliferativen prozessen
CA002560131A CA2560131A1 (en) 2004-03-30 2005-03-19 Compounds for treating proliferative processes
US12/963,250 US20110076238A1 (en) 2004-03-30 2010-12-08 Compounds for the treatment of proliferative processes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004016179A DE102004016179A1 (de) 2004-03-30 2004-03-30 Verbindungen zur Behandlung von proliferativen Prozessen

Publications (1)

Publication Number Publication Date
DE102004016179A1 true DE102004016179A1 (de) 2005-10-20

Family

ID=34962915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004016179A Withdrawn DE102004016179A1 (de) 2004-03-30 2004-03-30 Verbindungen zur Behandlung von proliferativen Prozessen

Country Status (6)

Country Link
US (2) US20060030579A1 (de)
EP (1) EP1732553A1 (de)
JP (1) JP2007530611A (de)
CA (1) CA2560131A1 (de)
DE (1) DE102004016179A1 (de)
WO (1) WO2005097126A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060079544A1 (en) * 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
US20110243924A1 (en) 2007-02-21 2011-10-06 Jorge Beleta Supervia Novel methods
EP2100598A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2100599A1 (de) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung
EP2510928A1 (de) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten
EA201590019A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
WO2014007767A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
CZ2014188A3 (cs) 2014-03-26 2015-10-07 Zentiva, K.S. Nové formy aclidinium chloridu a způsob jejich přípravy
WO2021021924A1 (en) * 2019-07-29 2021-02-04 Huang Cai Gu Formulation of antibody based drugs for treating lung cancer by inhalation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9918760D0 (en) * 1999-08-09 1999-10-13 Darwin Discovery Ltd Topical treatment
PL207870B1 (pl) * 2000-10-12 2011-02-28 Boehringer Ingelheim Pharma Krystaliczny monohydrat bromku tiotropium, sposób jego wytwarzania, środek leczniczy i zastosowanie
DE10050995A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
AU2002345016B2 (en) * 2001-06-22 2008-04-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203749A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20030191158A1 (en) * 2002-02-11 2003-10-09 Magee Thomas V. Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
JP4733350B2 (ja) * 2002-03-18 2011-07-27 シェーリング コーポレイション ケモカイン媒介疾患の併用治療
NZ538493A (en) * 2002-08-29 2007-10-26 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US7307076B2 (en) * 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole

Also Published As

Publication number Publication date
US20060030579A1 (en) 2006-02-09
US20110076238A1 (en) 2011-03-31
WO2005097126A1 (de) 2005-10-20
JP2007530611A (ja) 2007-11-01
EP1732553A1 (de) 2006-12-20
CA2560131A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
TW200606162A (en) Pyrazolopyridine derivatives
UA109459C2 (xx) ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
ATE539754T1 (de) Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
TW200626158A (en) Naphthaline derivatives
TW200628473A (en) Novel heterocycles
DE10337184A1 (de) Substituierte 3-Pyrrolidin-Indol-Derivate
DE102004016179A1 (de) Verbindungen zur Behandlung von proliferativen Prozessen
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
HK1146054A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
TW200740827A (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
ATE462438T1 (de) Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
TW200637817A (en) 5-aminoindole derivatives
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.

Legal Events

Date Code Title Description
R005 Application deemed withdrawn due to failure to request examination

Effective date: 20110331